Observational Study to Evalute the Efficacy and Safety of Avastin (Bevacizumab) in Addition to Platinum-Based Chemotherapy for First-Line Treatment of Participants With Non-Small Cell Lung Cancer (AVALANCHE)

Roche

Status: Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Treatments: Drug: Bevacizumab

Study type: Observational

Funder types: Industry

Identifiers

NCT03170284

ML21783

Details and patient eligibility

About

The purpose of this study is to examine the efficacy of Bevacizumab in addition to platinum-based chemotherapy for first-line treatment of participants with advanced stage (IIIB/IV) non-small cell lung cancer (NSCLC) other than predominantly squamous cell histology.

Enrollment: 150 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

In accordance with the SPC. Most important criteria:

• Histology or cytology proven inoperable, locally advanced,metastatic or recurrent (stage IIIB/IV) NSCLC other than predominantly squamous cell histology
• First-line treatment is indicated
• No previous treatment with Bevacizumab

Exclusion criteria

In accordance with the SPC. Most important criteria:

• Hypersensitivity to the active ingredient or to any of the excipients
• Hypersensitivity to products derived from Chinese hamster ovary (CHO) cells or to other recombinant human or humanized antibodies
• Pregnancy
• Bevacizumab is contraindicated in the presence of untreated central nervous system metastases

Trial design

150 participants in 1 patient group

Bevacizumab

Description:

Participants with advanced (stage IIIB/IV) NSCLC other than predominantly squamous cell histology receiving Bevacizumab in accordance with the summary product characteristics (SPC) is observed.

Treatment:

Drug: Bevacizumab